摘要
滤泡淋巴瘤（FL）是起源于滤泡生发中心的惰性非霍奇金淋巴瘤。第58届美国血液学会（AsH）年会上，多篇研究报道了FL治疗的最新进展。GA101联合化疗、苯达莫司汀（BR）联合呵替伊莫单抗（^90YIT）治疗中晚期FL的临床试验结果鼓舞人心；自体造血干细胞移植与非清髓同种异基因造血干细胞移植（allo-SCT）序贯治疗给复发、难治的FL患者带来更好的疗效，P13K抑制剂、bcl-2抑制剂、抗体一药物共轭物等新药接连涌现，复发、难治FL的治疗效果和缓解程度不断提高。
Follicular lymphoma （FL） is a kind of indolent non-Hodgkin lymphoma （iNHL）, which origins from follicle germinal center. Multiple researches reported the latest development about treatment of FL in the 58th American Society of Hematology （ASH） Annual Meeting. The outcomes of clinical trials in which GAIO1 combined with chemotherapy and bendamustine in combination with ^-ibritumomab tiuxetan for the advanced stage FL were exciting. Relapsed/refractory FL patients who receive tandem autologous followed by nonmyeloablative allogeneic transplantation could acquire preferable remissions. With the emerging of novel drugs including inhibitor of bcl-2 or PI3K and antibody drug conjugate, more and more improvements of efficacy and remission were made in the treatment of relapsed/refractory FL therapy and remission.
出处
《白血病．淋巴瘤》
CAS
2017年第1期21-23,27,共4页
Journal of Leukemia & Lymphoma
关键词
滤泡淋巴瘤
治疗进展
血液学会年会报道
Follicular lymphoma
Treatment progression
American Society of Hematology Annual Meeting
